Daprodustat Chinese generic name and drug alias

Daprodustat (Daprodustat) is a new oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), mainly used for the treatment of chronic kidney disease-related anemia. In China, daprostat has not yet been officially launched on the market, so it is not yet registered in the State Food and Drug Administration database, and the relevant medical insurance information is not covered. This means that there is currently a lack of official pricing in the domestic market. If patients are concerned about price and access, they need to pay attention to future listing information and legal channels. Daprostat is often referred to as "daplostat tablets" in Chinese literature and clinical data. This is its common Chinese name and the standard name used by medical institutions in drug management, prescription issuance and clinical medication guidance.

In the international market, the original drug of daprostat is developed by GlaxoSmithKline (GSK) and its trade name is Jesduvroq. In different countries and regions, R&D code names or other commercial names may also be used, but the active ingredient is Daprodustat. Jesduvroq, which is marketed overseas, is mainly used to improve anemia in patients with chronic kidney disease. It increases the level of endogenous erythropoietin by stabilizing HIF transcription factors and regulating iron metabolism, thereby reducing the need for red blood cell transfusions. It is worth noting that the ingredients of drugs with different trade names are the same, but the packaging specifications, approved indications and medication instructions may differ due to regional regulatory requirements.

In clinical practice, it is very important to understand the Chinese generic name and drug aliases of daprostat. On the one hand, it helps patients avoid confusion when seeking medical treatment, consulting international literature or transnational drug information; on the other hand, medical institutions also need to clarify the standard naming and possible trade names of drugs during pharmacy management, inventory management and prescription review. As HIF-PHI drugs are gradually promoted around the world, the possibility of daprostat being launched in China and included in medical insurance will gradually increase in the future. By then, it will be more convenient for patients to obtain drugs, and the price and payment policy will be more transparent.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat